Associations of CD73 expression with baseline characteristics of patients (N=138)
| Baseline characteristics (N) | CD73 expression | P value* | |||||
| Positive (N=42) | Negative (N=96) | ||||||
| High (n=22) | Low (n=20) | ||||||
| n | % | n | % | n | % | ||
| Metastatic status at presentation | 0.002 | ||||||
| Localized RCC (n=107) | 13 | 12 | 12 | 11 | 82 | 77 | |
| De novo mRCC (n=31) | 9 | 29 | 8 | 26 | 14 | 45 | |
| Histology | 0.11† | ||||||
| ccRCC (n=103) | 13 | 13 | 15 | 15 | 75 | 73 | |
| nccRCC (n=33) | 8 | 24 | 5 | 15 | 20 | 61 | |
| Papillary (n=16) | 6 | 38 | 5 | 31 | 5 | 31 | |
| Chromophobe (n=14) | 2 | 14 | . | . | 12 | 86 | |
| RCC unclassified (n=3) | . | . | . | . | 3 | 100 | |
| Unknown (n=2) | 1 | 50 | 1 | 50 | |||
| Sarcomatoid features | <0.0001 | ||||||
| No (n=124) | 15 | 12 | 15 | 12 | 94 | 76 | |
| Yes (n=10) | 5 | 50 | 4 | 40 | 1 | 10 | |
| Unknown (n=4) | 2 | 50 | 1 | 25 | 1 | 25 | |
| Fuhrman nuclear grade | 0.035 | ||||||
| G1-2 (n=75) | 11 | 15 | 7 | 9 | 57 | 76 | |
| G3 (n=38) | 5 | 13 | 8 | 21 | 25 | 66 | |
| G4 (n=22) | 6 | 27 | 5 | 23 | 11 | 50 | |
| Unknown (n=3) | 3 | 100 | |||||
| Pathological T stage | 0.004 | ||||||
| T1 (n=60) | 7 | 12 | 2 | 3 | 51 | 85 | |
| T2 (n=28) | 5 | 19 | 7 | 25 | 16 | 57 | |
| T3-4 (n=46) | 10 | 22 | 9 | 20 | 27 | 59 | |
| Unknown (n=4) | 2 | 50 | 2 | 50 | |||
| AJCC stage | <0.0001 | ||||||
| I (n=57) | 5 | 9 | 2 | 4 | 50 | 88 | |
| II (n=19) | 4 | 21 | 4 | 21 | 11 | 58 | |
| III (n=26) | 3 | 12 | 4 | 15 | 19 | 73 | |
| IV (n=34) | 10 | 29 | 9 | 27 | 15 | 44 | |
| Unknown (n=2) | 1 | 50 | 1 | 50 | |||
*Cochran-Armitage Trend test (for variables with two categories) and Jonckheere-Terpstra test (for variables with ≥3 ordered categories); unknown group was excluded from the comparison.
†P value is for comparison of ccRCC versus nccRCC.
AJCC, American Joint Committee on Cancer; ccRCC, clear cell renal cell carcinoma; mRCC, metastatic renal cell carcinoma; nccRCC, non-clear cell renal cell carcinoma; RCC, renal cell carcinoma.